Natasha Wehrli1, Hersh Chandarana1, Ely Felker1, Bachir Taouli, 1,2
1NYU Medical Center, New York, NY, United States; 2Mount Sinai School of Medicine, New York, NY, United States
Gd-EOB-DTPA is a recently FDA approved liver-specific contrast agent which combines a dynamic and a delayed phase of enhancement, approved to be used at a lower dose compared to extracellular agents (0.025 vs. 0.1 mmol/kg). In this study, we compared hepatic vascular conspicuity obtained with single and double dose Gd-EOB vs. Gd-DTPA at the dynamic phase, and found significantly better liver-to-vessel contrast ratio with Gd-DTPA compared to single dose Gd-EOB-DTPA. The liver-to-vessel contrast ratio improved when using a double dose Gd-EOB-DTPA.